Abstract:Hepatitis B virus (HBV) infection is the leading cause of chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC). This study reveals a distinct mechanism underlying the regulation of HBV replication. HBV activates homeobox A10 (HoxA10) in human hepatocytes, leukocytes, peripheral blood mononuclear cells (PBMCs), HepG2-NTCP cells, leukocytes isolated from CHB patients, and HBV-associated HCC tissues. HoxA10 in turn represses HBV replication in human hepatocytes, HepG2-NTCP cells, and BALB/c mice. Interestingly, we show that during early HBV infection, p38 mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) were activated to facilitate HBV replication; however, during late HBV infection, HoxA10 was induced to attenuate HBV replication. Detailed studies reveal that HoxA10 binds to p38 MAPK, recruits SH2-containing protein tyrosine phosphatase 1 (SHP-1) to facilitate SHP-1 in catalyzing dephosphorylation of p38 MAPK/STAT3, and thereby attenuates p38 MAPK/STAT3 activation and HBV replication. Furthermore, HoxA10 binds to the HBV enhancer element I (EnhI)/X promoter, competes with STAT3 for binding of the promoter, and thereby represses HBV transcription. Taken together, these results show that HoxA10 attenuates HBV replication through repressing the p38 MAPK/STAT3 pathway by two approaches: HoxA10 interacts with p38 MAPK and recruits SHP-1 to repress HBV replication, and HoxA10 binds to the EnhI/X promoter and competes with STAT3 to attenuate HBV transcription. Thus, the function of HoxA10 is similar to the action of interferon (IFN) in terms of inhibition of HBV infection; however, the mechanism of HoxA10-mediated repression of HBV replication is different from the mechanism underlying IFN-induced inhibition of HBV infection. IMPORTANCE Two billion people have been infected with HBV worldwide; about 240 million infected patients developed chronic hepatitis B (CHB), and 650,000 die each year from liver cirrhosis (LC) or hepatocellular carcinoma (HCC). This work elucidates a mechanism underlying the control of HBV replication. HBV infection activates HoxA10, a regulator of cell differentiation and cancer progression, in human cells and patients with CHB and HCC. HoxA10 subsequently inhibits HBV replication in human tissue culture cells and mice. Additionally, HoxA10 interacts with p38 MAPK to repress the activation of p38 MAPK and STAT3 and recruits and facilitates SHP-1 to catalyze the dephosphorylation of p38 MAPK and STAT3. Moreover, HoxA10 competes with STAT3 for binding of the HBV X promoter to repress HBV transcription. Thus, this work reveals a negative regulatory mechanism underlying the control of HBV replication and provides new insights into the development of potential agents to control HBV infection.

Effect of P-body component Mov10 on HCV virus production and infectivity

Host MOV10 is Induced to Restrict Herpes Simplex Virus 1 Lytic Infection by Promoting Type I Interferon Response.

RNA Helicase MOV10 Functions As a Co-Factor of HIV-1 Rev to Facilitate Rev/RRE-dependent Nuclear Export of Viral Mrnas.

MOV10 interacts with Enterovirus 71 genomic 5'UTR and modulates viral replication.

Moloney Leukemia Virus 10 (MOV10) Inhibits the Degradation of APOBEC3G Through Interference with the Vif-mediated Ubiquitin–proteasome Pathway

The MOV10 RNA helicase is a dosage-dependent host restriction factor for LINE1 retrotransposition in mice

Host Protein Moloney Leukemia Virus 10 (MOV10) Acts as a Restriction Factor of Influenza A Virus by Inhibiting the Nuclear Import of the Viral Nucleoprotein

The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10

Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein

The MOV10 Helicase Inhibits LINE-1 Mobility

Modulation of hepatitis C virus RNA abundance and virus release by dispersion of processing bodies and enrichment of stress granules.

Mechanistic Insights into the Protection Effect of Argonaute–RNA Complex on the HCV Genome

Regulation of Multiple Stages of Hepadnavirus Replication by the Carboxyl-Terminal Domain of Viral Core Protein in Trans

Expression of Interferon-Stimulated Gene ISG20 and Investigation of Its Antiviral Effect on HCV Replicon

Biological and RNA regulatory function of MOV10 in mammalian germ cells

Inhibition of the HCV Core Protein on the Immune Response to HBV Surface Antigen and on HBV Gene Expression and Replication in Vivo.

[Regulation Mechanism of HCV NS5A on P53 Protein Transactivity].

PPP2R5D promotes hepatitis C virus infection by binding to viral NS5B and enhancing viral RNA replication

HoxA10 Facilitates SHP-1-Catalyzed Dephosphorylation of P38 MAPK/STAT3 to Repress Hepatitis B Virus Replication by a Feedback Regulatory Mechanism

Block Effect on HCV Infection by HMGB1 Released from Virus-Infected Cells: an Insight from Mathematical Modeling

Regulatory Polymorphisms in the Promoter of CXCL10 Gene and Disease Progression in Male Hepatitis B Virus Carriers.